Marker Therapeutics Inc (MRKR)

[poods]

Of course Multi-TAA works. Look at all the CRs as a stand alone treatment in heavily pretreated lymphoma patients. Same product as used in pancreatic cancer. Considering just pancreatic cancer, the chance of a CR with Folfirinox alone was 1/171 in the largest trial for metastatic disease. You can do the math but we have had thus far 3 patients progress on Folfirinox + multi-TAA in group A, 2 after cells were discontinued after the sixth dose,, and 1 CR thus far. Even given that group A was selected for SD on folfirinox (70% will be stable), the chance of seeing a CR in 4 patients was fairly small (~1/30). Now consider what we might have seen if we started cells after the first dose of folfirinox and then continued dosing until a CR was achieved or the patients progressed. Then consider what we might see when we actually include several antigens in the pep mix that are expressed on pancreatic cancer in high concentration. Also drugs are usually increased in dosing to optimize response until dose limiting toxicity is reached. We are using very low dosing relative to other cell therapies and have seen no toxicities of significance.
Bottom line: Anyone who studies the totality of the data (including the immunological responses) should come to the conclusion that this works in lymphoma and probably in pancreatic cancer, and there is also ample opportunity for enhancement.